ATE266092T1 - Verwendung eines von einem viralen vektor kodierten cytochrom p450 gens, in kombination mit einem chemotherapeutischen mittel, zur selektiven zerstörung neoplastischer zellen - Google Patents

Verwendung eines von einem viralen vektor kodierten cytochrom p450 gens, in kombination mit einem chemotherapeutischen mittel, zur selektiven zerstörung neoplastischer zellen

Info

Publication number
ATE266092T1
ATE266092T1 AT95929543T AT95929543T ATE266092T1 AT E266092 T1 ATE266092 T1 AT E266092T1 AT 95929543 T AT95929543 T AT 95929543T AT 95929543 T AT95929543 T AT 95929543T AT E266092 T1 ATE266092 T1 AT E266092T1
Authority
AT
Austria
Prior art keywords
cytochrome
neoplastic cells
chemotherapeutic agent
combination
viral vector
Prior art date
Application number
AT95929543T
Other languages
English (en)
Inventor
E Antonio Chiocca
David J Waxman
Ming X Wei
Xandra O Breakefield
Ling Chen
Original Assignee
Gen Hospital Corp
Univ Boston
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE266092(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp, Univ Boston, Dana Farber Cancer Inst Inc filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE266092T1 publication Critical patent/ATE266092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95929543T 1994-08-17 1995-08-15 Verwendung eines von einem viralen vektor kodierten cytochrom p450 gens, in kombination mit einem chemotherapeutischen mittel, zur selektiven zerstörung neoplastischer zellen ATE266092T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29150094A 1994-08-17 1994-08-17
US08/330,523 US5688773A (en) 1994-08-17 1994-10-28 Method of selectively destroying neoplastic cells
PCT/US1995/010365 WO1996004789A1 (en) 1994-08-17 1995-08-15 A method of selectively destroying neoplastic cells

Publications (1)

Publication Number Publication Date
ATE266092T1 true ATE266092T1 (de) 2004-05-15

Family

ID=26966824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929543T ATE266092T1 (de) 1994-08-17 1995-08-15 Verwendung eines von einem viralen vektor kodierten cytochrom p450 gens, in kombination mit einem chemotherapeutischen mittel, zur selektiven zerstörung neoplastischer zellen

Country Status (7)

Country Link
US (1) US5688773A (de)
EP (1) EP0776161B2 (de)
JP (1) JP4509221B2 (de)
AT (1) ATE266092T1 (de)
CA (1) CA2197677C (de)
DE (1) DE69532994T3 (de)
WO (1) WO1996004789A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4119952B2 (ja) 1995-06-27 2008-07-16 バヴァリアン・ノルディック・アクティーゼルスカブ ウイルス粒子産生カプセル化細胞
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
PL188323B1 (pl) * 1996-03-27 2005-01-31 Bavarian Nordic As Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny
US6210664B1 (en) * 1996-04-08 2001-04-03 New York University Medical Center Method for gene transfer to the central nervous system
US6207648B1 (en) 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
CA2325561A1 (en) * 1998-04-22 1999-10-28 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6841537B1 (en) 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6841538B1 (en) 1998-04-22 2005-01-11 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and radio therapy
CA2327506A1 (en) 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
WO2000014256A1 (en) * 1998-09-04 2000-03-16 Genotherapeutics, Inc. Gene therapy for treatment of cancer
AU6328099A (en) * 1998-09-21 2000-04-10 Transgene S.A. Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
GB0122803D0 (en) * 2001-09-21 2001-11-14 Oxford Biomedica Ltd Vector
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
US6573090B1 (en) 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
IL145899A0 (en) * 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
US6770632B1 (en) 1999-07-16 2004-08-03 The General Hospital Corporation Folypolyglutamyl synthetase gene transfer to enhance antifolate
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
EP1229934B1 (de) 1999-10-01 2014-03-05 Immunogen, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
WO2001059152A2 (en) * 2000-02-09 2001-08-16 Epidauros Biotechnologie Ag Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
US7214515B2 (en) * 2001-01-05 2007-05-08 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic DNA inserts
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
CA2349506C (en) * 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
WO2003025191A2 (en) * 2001-09-21 2003-03-27 Oxford Biomedica (Uk) Limited Pseudotyped retroviral vector system
US7618621B2 (en) 2002-01-14 2009-11-17 The Board Of Trustees Of The University Of Illinois Mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof
EP1539189A4 (de) * 2002-03-25 2007-05-09 Univ Boston Verfahren zur verwendung von anti-apoptose-faktoren in der genexpression
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7632656B2 (en) * 2003-03-04 2009-12-15 Cellseed Inc. High performance liquid chromatography with an aqueous mobile phase for analysis of drug and its metabolite
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
PL2531206T3 (pl) 2010-02-04 2017-12-29 Morphotek, Inc. Polipeptydy i koniugaty chlorotoksyny i ich zastosowanie
EP3165533B1 (de) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin-varianten und -konjugate sowie verfahren zu deren verwendung
EP3473708B1 (de) 2012-07-24 2021-01-27 The General Hospital Corporation Onkolytische virustherapie für resistente tumore
BR112015013515A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
EP3082834B1 (de) 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Von stammzellen abgegebener onkolytischer herpes-simplex-virus und verfahren zur behandlung von hirntumoren
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
MX2015006813A (es) * 2015-05-29 2016-11-28 Univ Nac Autónoma De México Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164313A (en) * 1987-06-05 1992-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant vaccinia virus encoding cytochromes P-450
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
CA2158936C (en) † 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes

Also Published As

Publication number Publication date
JP4509221B2 (ja) 2010-07-21
US5688773A (en) 1997-11-18
DE69532994D1 (de) 2004-06-09
DE69532994T2 (de) 2005-05-25
DE69532994T3 (de) 2008-02-07
JPH10504308A (ja) 1998-04-28
CA2197677A1 (en) 1996-02-22
EP0776161B1 (de) 2004-05-06
EP0776161B2 (de) 2007-09-12
EP0776161A1 (de) 1997-06-04
EP0776161A4 (de) 1999-04-07
WO1996004789A1 (en) 1996-02-22
CA2197677C (en) 2009-03-10

Similar Documents

Publication Publication Date Title
ATE266092T1 (de) Verwendung eines von einem viralen vektor kodierten cytochrom p450 gens, in kombination mit einem chemotherapeutischen mittel, zur selektiven zerstörung neoplastischer zellen
EP1044717A3 (de) Vorrichtung and Verfahren zur elektrischen Entionisierung mit Polaritätsumschaltung und Doppelumschaltung
IL139974A0 (en) Culture medium for culture of animal cell and method for producing protein using same
DK0554240T3 (da) Ekspression af herbicidmetaboliserende cytochromer P450
AU5700094A (en) Modified cutinases, dna, vector and host
NZ336467A (en) Modulators of tissue regeneration using DNA enclding a kidney injury molecule KIM
GB8308236D0 (en) Dna vectors
DE69532087D1 (de) Föderanlage zum postiven erzeugen von zwischenräumen
DE59700432D1 (de) Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, oder ligninhaltigen Materialien sowie Verfahren zu seiner Anwendung
DE59800946D1 (de) Verfahren zur herstellung von expandierbaren styrolpolymerisaten
EP0476953A3 (en) Viral targeted destruction of neoplastic cells
EP0829491A3 (de) Verfahren zur Beendigung der Gasphasenpolymerisation von Olefinen, Verfahren zum Starten der Polymerisation und dafür geeigneter Reaktor
AU3409295A (en) Regulatable elimination of gene expression, gene product function and engineered host cells
CA2095300A1 (en) Use of genetically modified cells to treat defects, disease or damage of the central nervous system
WO1998037185A3 (en) Vectors for controlled gene expression
PL309388A1 (en) Modified cutinases, dna, vector and host
ATE204308T1 (de) Verfahren zur herstellung von schutzkolloidstabilisierten vinylaromat-1.3-dien- copolymerisaten
DK0906443T3 (da) Generering af replikerende molekyler in vivo
ATE188203T1 (de) Verbesserter biologischer abbau von organischen abfällen
ATE313336T1 (de) Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen
NO158808C (no) Fremgangsmaate ved polymerisasjon av vinylklorid, og vanndispersjon for anvendelse ved polymeriseringen.
HK1019751A1 (en) Tissue specific expression of retinoblastoma protein.
EP0733057A4 (de) Ursprung von replikationskomplex-genen, proteinen und verfahren
ATE124450T1 (de) Rna mit endonuclease- und antisense-aktivität, ihre herstellung und ihre verwendung.
SE9802457L (sv) Förfarande och apparat för konstant envellop-kvadratur- kvadratur-amplitudmodulering

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0776161

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0776161

Country of ref document: EP